Tom Bird

Tom Bird

Partner and Co-Head of North American Transactions

New York Office

(212) 257-5806

Tom joined Torreya Partners in 2007 as a member of the founding team. He is co-Head of North American Strategic Transactions Advisory.

Tom has deep expertise in the world of specialty pharmaceuticals, life science tools, generic products, and pharma manufacturing. Tom is also an accomplished strategic planner with a focus on planning process, development and implementation.

Previously, Tom was VP, Corporate Development at Cambrex, where he was involved in a number of divestitures and acquisitions and the President of the Biosciences Group of Cambrex, where he built the Biowhittaker division through acquisitions into a powerhouse in the supply business of cell biology, stem cells, electrophoresis gels and reagents. Before Cambrex, Tom had served President of Nepera Chemical, Cuno, and Consumer Products division of Sherwin-Williams. Tom received a B.A. from Muhlenberg College and conducted graduate studies at the University of New Hampshire.

Some of Tom’s transaction experience prior to joining Torreya includes the sale of Cambrex’s Manufacturing Facilities in Ireland and Belgium (2006); the sale of Cambrex Bio-Subsidiaries to Lonza, $460 million (2006); Cambrex’s Acquisition of Cutanogen (2006); Cambrex’s, Acquisition of Genolife (2004); Cambrex’s Sale of Rutherford Chemicals (2003); Cambrex’s, Acquisition of Lumitech (2001); Cambrex’s, Alliance with (2000); Cambrex’s Equity Investment and Alliance with Osiris Therapeutics (1999); Cambrex’s Acquisition of Poetic Technologies (1999) and Cambrex’s Acquisition of BioProducts Business from FMC (1999).

Tom is a registered representative with Financial West Group.